Literature DB >> 33633741

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy.

Weiqin Jiang1, Yinjun He1, Wenguang He2, Guosheng Wu1, Xile Zhou1, Qinsong Sheng1, Weixiang Zhong3, Yimin Lu4, Yongfeng Ding5, Qi Lu6, Feng Ye1, Hanju Hua1.   

Abstract

Tumor-specific CD8+T cells are exposed to persistent antigenic stimulation which induces a dysfunctional state called "exhaustion." Though functioning to limit damage caused by immune response, T cell exhaustion leads to attenuated effector function whereby cytotoxic CD8+T cells fail to control tumor progression in the late stage. This pathway is a dynamic process from activation to "progenitor exhaustion" through to "terminally exhaustion" with distinct properties. With the rapid development of immunotherapy via enhancing T cell function, new studies are dissecting the mechanisms and identifying specific biomarkers of dynamic differentiation during the process of exhaustion. Further, although immune checkpoint inhibitors (ICIs) have achieved great success in clinical practice, most patients still show limited efficacy to ICIs. The expansion and differentiation of progenitor exhausted T cells explained the success of ICIs while the depletion of the progenitor T cell pool and the transient effector function of terminally exhausted T cells accounted for the failure of immune monotherapy in the context of exorbitant tumor burden. Thus, combination strategies are urgent to be utilized based on the reduction of tumor burden or the expansion of the progenitor T cell pool. In this review, we aim to introduce the concept of homeostasis of the activated and exhausted status of CD8+T cells in the tumor immune microenvironment, and present recent findings on dynamic differentiation process during T cell exhaustion and the implications for combination strategies in immune therapy.
Copyright © 2021 Jiang, He, He, Wu, Zhou, Sheng, Zhong, Lu, Ding, Lu, Ye and Hua.

Entities:  

Keywords:  CD8+ T cell activation; CD8+ T cell exhaustion; differentiation; immunotherapy; tumor microenvironment

Year:  2021        PMID: 33633741      PMCID: PMC7902023          DOI: 10.3389/fimmu.2020.622509

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  94 in total

Review 1.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 2.  Role of IL-2 in cancer immunotherapy.

Authors:  Tao Jiang; Caicun Zhou; Shengxiang Ren
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

3.  An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.

Authors:  Ugur Sahin; Petra Oehm; Evelyna Derhovanessian; Robert A Jabulowsky; Mathias Vormehr; Maike Gold; Daniel Maurus; Doreen Schwarck-Kokarakis; Andreas N Kuhn; Tana Omokoko; Lena M Kranz; Mustafa Diken; Sebastian Kreiter; Heinrich Haas; Sebastian Attig; Richard Rae; Katarina Cuk; Alexandra Kemmer-Brück; Andrea Breitkreuz; Claudia Tolliver; Janina Caspar; Juliane Quinkhardt; Lisa Hebich; Malte Stein; Alexander Hohberger; Isabel Vogler; Inga Liebig; Stephanie Renken; Julian Sikorski; Melanie Leierer; Verena Müller; Heidrun Mitzel-Rink; Matthias Miederer; Christoph Huber; Stephan Grabbe; Jochen Utikal; Andreas Pinter; Roland Kaufmann; Jessica C Hassel; Carmen Loquai; Özlem Türeci
Journal:  Nature       Date:  2020-07-29       Impact factor: 49.962

4.  T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections.

Authors:  Daniel T Utzschneider; Mélanie Charmoy; Vijaykumar Chennupati; Laurène Pousse; Daniela Pais Ferreira; Sandra Calderon-Copete; Maxime Danilo; Francesca Alfei; Maike Hofmann; Dominik Wieland; Sylvain Pradervand; Robert Thimme; Dietmar Zehn; Werner Held
Journal:  Immunity       Date:  2016-08-16       Impact factor: 31.745

5.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Authors:  Thomas J Lynch; Igor Bondarenko; Alexander Luft; Piotr Serwatowski; Fabrice Barlesi; Raju Chacko; Martin Sebastian; Joel Neal; Haolan Lu; Jean-Marie Cuillerot; Martin Reck
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 7.  Mechanisms and functional significance of tumour-induced dendritic-cell defects.

Authors:  Dmitry Gabrilovich
Journal:  Nat Rev Immunol       Date:  2004-12       Impact factor: 53.106

Review 8.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

9.  An immunogenic personal neoantigen vaccine for patients with melanoma.

Authors:  Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

10.  Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence.

Authors:  R Ahmed; A Salmi; L D Butler; J M Chiller; M B Oldstone
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  23 in total

Review 1.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

2.  Immunological role and prognostic potential of CLEC10A in pan-cancer.

Authors:  Yan Qin; Lulu Wang; Lihua Zhang; Jiasheng Li; Lixian Liao; Lihaoyun Huang; Wei Li; Jianrong Yang
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

3.  Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus.

Authors:  Łukasz Zapała; Michał Kunc; Sumit Sharma; Rafał Pęksa; Marta Popęda; Wojciech Biernat; Piotr Radziszewski
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-30       Impact factor: 4.322

4.  "Derived Multiple Allogeneic Protein Paracrine Signaling (d-MAPPS)" Enhances T Cell-Driven Immune Response to Murine Mammary Carcinoma.

Authors:  Carl Randall Harrell; Dragica Pavlovic; Dragana Miloradovic; Milica Dimitrijevic Stojanovic; Valentin Djonov; Vladislav Volarevic
Journal:  Anal Cell Pathol (Amst)       Date:  2022-06-15       Impact factor: 4.133

5.  Evidence of Omics, Immune Infiltration, and Pharmacogenomics for BATF in a Pan-Cancer Cohort.

Authors:  Chenguang Jia; Yihui Ma; Mengyang Wang; Wen Liu; Feng Tang; Jincao Chen
Journal:  Front Mol Biosci       Date:  2022-04-29

Review 6.  CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity.

Authors:  Jing Yuan Tan; Muhammed Haiqal Low; Yunxin Chen; Francesca Lorraine Wei Inng Lim
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

7.  Reprogrammed CD8+ T-Lymphocytes Isolated from Bone Marrow Have Anticancer Potential in Lung Cancer.

Authors:  Evgenii G Skurikhin; Olga Pershina; Natalia Ermakova; Angelina Pakhomova; Darius Widera; Mariia Zhukova; Edgar Pan; Lubov Sandrikina; Lena Kogai; Nikolai Kushlinskii; Sergey G Morozov; Aslan Kubatiev; Alexander Dygai
Journal:  Biomedicines       Date:  2022-06-19

8.  Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity.

Authors:  Caleb R Stoltzfus; Ramya Sivakumar; Leo Kunz; Brandy E Olin Pope; Elena Menietti; Dario Speziale; Roberto Adelfio; Marina Bacac; Sara Colombetti; Mario Perro; Michael Y Gerner
Journal:  Front Immunol       Date:  2021-08-05       Impact factor: 7.561

9.  A Novel Prognostic Predictor of Immune Microenvironment and Therapeutic Response in Kidney Renal Clear Cell Carcinoma based on Necroptosis-related Gene Signature.

Authors:  Wenwei Chen; Wenfeng Lin; Liang Wu; Abai Xu; Chunxiao Liu; Peng Huang
Journal:  Int J Med Sci       Date:  2022-01-24       Impact factor: 3.738

10.  A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.

Authors:  Xiaohan Zhou; Jun Du; Chengdong Liu; Hanyi Zeng; Yuting Chen; Li Liu; Dehua Wu
Journal:  Front Immunol       Date:  2021-07-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.